---
layout: default
title: Docetaxel
description: "Docetaxel çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æœ€é«˜è­‰æ“šç­‰ç´š L1ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 61
evidence_level: L1
indication_count: 10
---

# Docetaxel

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L1</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Docetaxelï¼šå¾HER2é™½æ€§ä¹³ç™Œåˆ°å¥³æ€§ä¹³è…ºç™Œ

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Docetaxel å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Docetaxel åŸæœ¬ç”¨æ–¼æ²»ç™‚ HER2 é™½æ€§ä¹³ç™ŒåŠè½‰ç§»æ€§èƒƒç™Œã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**å¥³æ€§ä¹³è…ºç™Œ (female breast carcinoma)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **è¶…é50å€‹è‡¨åºŠè©¦é©—**å’Œ **å¤šç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | HER2é™½æ€§æ—©æœŸä¹³ç™Œã€è½‰ç§»æ€§ä¹³ç™Œã€è½‰ç§»æ€§èƒƒç™Œ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | å¥³æ€§ä¹³è…ºç™Œã€Ewing sarcomaã€well-differentiated fetal adenocarcinoma of the lungã€small cell lung carcinomaã€primary pulmonary lymphomaã€botryoid-type embryonal rhabdomyosarcoma of the vaginaã€pulmonary blastomaã€rhabdomyosarcoma (disease)ã€embryonal extrahepatic bile duct rhabdomyosarcomaã€parameningeal embryonal rhabdomyosarcoma |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.90% |
| è­‰æ“šç­‰ç´š | L1 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µ |
| å»ºè­°æ±ºç­– | Proceed |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. female breast carcinoma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.90%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

<p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ">
Docetaxel å±¬æ–¼ taxane é¡æŠ—è…«ç˜¤è—¥ç‰©ï¼Œé€éä¿ƒé€²å¾®ç®¡è›‹ç™½èšåˆä¸¦æŠ‘åˆ¶å¾®ç®¡è§£èšä¾†å¹²æ“¾ç´°èƒåˆ†è£‚ï¼Œ
å°è‡´ç´°èƒé€±æœŸåœæ»¯åœ¨ G2/M æœŸã€‚å…¶åœ¨ä¹³ç™Œæ²»ç™‚ä¸­çš„ç™‚æ•ˆå·²è¢«å»£æ³›è­‰å¯¦ï¼Œ
åŒ…æ‹¬èˆ‡ trastuzumabã€carboplatin ç­‰è—¥ç‰©ä½µç”¨çš„å¤šç¨®æ²»ç™‚æ–¹æ¡ˆã€‚
é æ¸¬å…¶å°å¥³æ€§ä¹³è…ºç™Œæœ‰æ•ˆå…·æœ‰æ˜ç¢ºçš„æ©Ÿè½‰åŸºç¤ã€‚
</p>

<div class="key-takeaway">
æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚
</div>

### è‡¨åºŠè©¦é©—

| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | äººæ•¸ | ä¸»è¦ç™¼ç¾ |
|---------|------|------|------|---------|
| [NCT00002707](https://clinicaltrials.gov/study/NCT00002707) | Phase 3 | COMPLETED | 2411 | æ¯”è¼ƒè¡“å‰ AC åŒ–ç™‚åˆä½µ docetaxel çš„æ•ˆæœ |
| [NCT03588091](https://clinicaltrials.gov/study/NCT03588091) | Phase 3 | COMPLETED | 355 | è©•ä¼° pyrotinib è¯åˆ trastuzumab å’Œ docetaxel çš„æ–°è¼”åŠ©æ²»ç™‚ |
| [NCT01583426](https://clinicaltrials.gov/study/NCT01583426) | Phase 3 | COMPLETED | 1229 | æ¯”è¼ƒ nab-paclitaxel èˆ‡ solvent-based paclitaxel ä½œç‚ºæ–°è¼”åŠ©åŒ–ç™‚ |
| [NCT00887536](https://clinicaltrials.gov/study/NCT00887536) | Phase 3 | COMPLETED | 1613 | æ¯”è¼ƒ TC+bevacizumab èˆ‡ TC åŠ TAC åœ¨ HER2 é™°æ€§ä¹³ç™Œçš„è¼”åŠ©æ²»ç™‚ |
| [NCT00047255](https://clinicaltrials.gov/study/NCT00047255) | Phase 3 | COMPLETED | 263 | æ¯”è¼ƒ docetaxel+trastuzumab èˆ‡ docetaxel+carboplatin+trastuzumab |

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [28398846](https://pubmed.ncbi.nlm.nih.gov/28398846/) | 2017 | RCT | J Clin Oncol | ABC è©¦é©—æ¯”è¼ƒ TC èˆ‡ TaxAC æ–¹æ¡ˆåœ¨æ—©æœŸä¹³ç™Œçš„ç™‚æ•ˆ |
| [7595719](https://pubmed.ncbi.nlm.nih.gov/7595719/) | 1995 | Review | J Clin Oncol | Docetaxel çš„è‡¨åºŠå‰å’Œè‡¨åºŠæ¦‚è¿° |
| [27997437](https://pubmed.ncbi.nlm.nih.gov/27997437/) | 2016 | Cohort | N/A | Docetaxel åŒ–ç™‚èˆ‡ä¹³ç™Œç›¸é—œæ·‹å·´æ°´è…«çš„é—œè¯ |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. Ewing sarcoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.90%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. well-differentiated fetal adenocarcinoma of the lung</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.84%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.84%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. small cell lung carcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.83%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.83%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. primary pulmonary lymphoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.83%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.83%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. botryoid-type embryonal rhabdomyosarcoma of the vagina</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.80%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.80%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. pulmonary blastoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.80%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.80%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. rhabdomyosarcoma (disease)</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.79%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.79%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. embryonal extrahepatic bile duct rhabdomyosarcoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.76%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.76%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. parameningeal embryonal rhabdomyosarcoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.76%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.76%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| å¤šå¼µè¨±å¯è­‰ | æ›²æ–¯è‹¥å‡æ™¶æ³¨å°„åŠ‘150æ¯«å…‹ | æ³¨å°„åŠ‘ | HER2é™½æ€§æ—©æœŸä¹³ç™Œè¼”åŠ©æ²»ç™‚ã€è½‰ç§»æ€§ä¹³ç™Œã€è½‰ç§»æ€§èƒƒç™Œ |

## ç´°èƒæ¯’æ€§

| é …ç›® | å…§å®¹ |
|------|------|
| ç´°èƒæ¯’æ€§åˆ†é¡ | å‚³çµ±ç´°èƒæ¯’æ€§è—¥ç‰© (Taxaneé¡) |
| éª¨é«“æŠ‘åˆ¶é¢¨éšª | é«˜åº¦ (å—œä¸­æ€§ç™½è¡€çƒæ¸›å°‘ç‚ºä¸»è¦æ¯’æ€§) |
| è‡´åæ€§åˆ†ç´š | ä½åº¦ |
| ç›£æ¸¬é …ç›® | CBCï¼ˆå«åˆ†é¡ï¼‰ã€è‚åŠŸèƒ½ã€å‘¨é‚Šç¥ç¶“ç—…è®Š |
| è™•ç½®é˜²è­· | éœ€ä¾ç´°èƒæ¯’æ€§è—¥ç‰©è™•ç½®è¦ç¯„æ“ä½œ |

## å®‰å…¨æ€§è€ƒé‡

- **ä¸»è¦ä¸è‰¯åæ‡‰**ï¼šå—œä¸­æ€§ç™½è¡€çƒæ¸›å°‘ã€éæ•åæ‡‰ã€å‘¨é‚Šç¥ç¶“ç—…è®Šã€æ¶²é«”æ»¯ç•™
- **é é˜²æªæ–½**ï¼šéœ€é å…ˆçµ¦äºˆ dexamethasone ä»¥æ¸›å°‘æ¶²é«”æ»¯ç•™å’Œéæ•åæ‡‰

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**è‘¡è„æŸšæ± (grapefruit juice)** ğŸŸ¢ Minor
- å½±éŸ¿ï¼šCoadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may significantly increase the plasma concentrations of docetaxel, which is a substrate of the isoenzyme.  Current data sugges...
- å»ºè­°ï¼šThe use of docetaxel in combination with grapefruit and grapefruit juice should generally be avoided.  If concomitant use is required, a reduced dosage of docetaxel should be considered, particularly ...

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**è–ç´„ç¿°è‰ï¼ˆè²«è‘‰é€£ç¿¹ï¼‰** ğŸ”´ Major
- å½±éŸ¿ï¼šè–ç´„ç¿°è‰é™ä½åŒ–ç™‚è—¥ç‰©ç™‚æ•ˆ
- å»ºè­°ï¼šåŒ–ç™‚æœŸé–“ç¦ç”¨æ‰€æœ‰è‰è—¥è£œå……å“



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Alcoholism** ğŸŸ¡ Moderate
- The alcohol content in a dose of docetaxel injection may affect the central nervous system.  Cases of intoxication have been reported with some formulations of docetaxel due to the alcohol content.  Close monitoring is recommended in alcoholic patien...

**Paresthesia** ğŸŸ¡ Moderate
- Severe neurosensory symptoms such as paresthesia, dysesthesia, and pain have been reported during docetaxel therapy.  Therapy with docetaxel should be administered cautiously to patients with or predisposition to neurosensory symptoms.  Although reve...

**Infections** ğŸŸ¢ Minor
- Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All pat...

**Edema** ğŸŸ¢ Minor
- Severe fluid retention characterized by peripheral edema, generalized edema, pleural effusion, dyspnea at rest, cardiac tamponade, or abdominal distention due to ascites has been reported during docetaxel therapy.   Therapy with docetaxel should be a...

**Eye Diseases** ğŸŸ¢ Minor
- Cystoid macular edema has been reported with the use of docetaxel.  Patients with impaired vision should undergo a prompt and comprehensive ophthalmologic examination prior to therapy with this agent.  If cystoid macular edema is diagnosed, treatment...

*å¦æœ‰ 2 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed**

**ç†ç”±ï¼š**
Docetaxel åœ¨å¥³æ€§ä¹³è…ºç™Œçš„è‡¨åºŠæ‡‰ç”¨å·²æœ‰å¤§é‡ Phase 3 è©¦é©—æ”¯æŒï¼Œç™‚æ•ˆè­‰æ“šå……åˆ†ï¼Œ
ä¸”ä½œç”¨æ©Ÿè½‰èˆ‡é æ¸¬é©æ‡‰ç—‡é«˜åº¦ç›¸é—œã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- é‡å°ç‰¹å®šä¹³ç™Œäºå‹çš„ç²¾æº–æ²»ç™‚æ–¹æ¡ˆå„ªåŒ–
- æ¸›å°‘å‘¨é‚Šç¥ç¶“ç—…è®Šç­‰é•·æœŸæ¯’æ€§çš„ç­–ç•¥ç ”ç©¶


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Temozolomide]({{ "/drugs/temozolomide/" | relative_url }}) - è­‰æ“šç­‰ç´š L1
- [Anastrozole]({{ "/drugs/anastrozole/" | relative_url }}) - è­‰æ“šç­‰ç´š L1
- [Icatibant]({{ "/drugs/icatibant/" | relative_url }}) - è­‰æ“šç­‰ç´š L1
- [Naftifine]({{ "/drugs/naftifine/" | relative_url }}) - è­‰æ“šç­‰ç´š L1
- [Ipratropium]({{ "/drugs/ipratropium/" | relative_url }}) - è­‰æ“šç­‰ç´š L1

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Docetaxelè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/docetaxel/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_docetaxel,
  title = {Docetaxelè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/docetaxel/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
